The weight-loss drug Zepbound was linked to a reduction in obstructive sleep apnea (OSA), according to new research. Pharmaceutical manufacturer Eli Lilly on Wednesday said injections of its obesity drug tirzepatide — commonly known as Zepbound — “significantly reduced” the number of sleep apnea events during one’s sleep when compared to a placebo.